Maat Pharma SA (PA:MAAT) — Market Cap & Net Worth
Market Cap & Net Worth: Maat Pharma SA (MAAT)
Maat Pharma SA (PA:MAAT) has a market capitalization of $62.59 Million (€53.54 Million) as of June 21, 2026. Listed on the PA stock exchange, this France-based company holds position #21065 globally and #332 in its home market, demonstrating a 0.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maat Pharma SA's stock price €2.86 by its total outstanding shares 18751521 (18.75 Million). Review Maat Pharma SA (MAAT) financial obligations to assess the company's total debt and financial obligations.
Maat Pharma SA Market Cap History: 2021 to 2026
Maat Pharma SA's market capitalization history from 2021 to 2026. Data shows change from $292.67 Million to $62.59 Million (-29.10% CAGR).
Index Memberships
Maat Pharma SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$255.24 Billion | 0.02% | #28 of 36 |
Weight: Maat Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Maat Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maat Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
54.26x
Maat Pharma SA's market cap is 54.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $292.67 Million | $972.00K | -$9.02 Million | 301.10x | N/A |
| 2022 | $175.38 Million | $1.43 Million | -$13.71 Million | 122.64x | N/A |
| 2023 | $153.02 Million | $2.23 Million | -$19.72 Million | 68.68x | N/A |
| 2024 | $174.50 Million | $3.22 Million | -$28.90 Million | 54.26x | N/A |
Competitor Companies of MAAT by Market Capitalization
Companies near Maat Pharma SA in the global market cap rankings as of June 21, 2026.
Key companies related to Maat Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Maat Pharma SA Historical Marketcap From 2021 to 2026
Between 2021 and today, Maat Pharma SA's market cap moved from $292.67 Million to $ 62.59 Million, with a yearly change of -29.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €62.59 Million | -40.64% |
| 2025 | €105.45 Million | -39.57% |
| 2024 | €174.50 Million | +14.04% |
| 2023 | €153.02 Million | -12.75% |
| 2022 | €175.38 Million | -40.07% |
| 2021 | €292.67 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of Maat Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $62.59 Million USD |
| MoneyControl | $62.59 Million USD |
| MarketWatch | $62.59 Million USD |
| marketcap.company | $62.59 Million USD |
| Reuters | $62.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more